Press releases

Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside...

Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and...

Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis...

Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021...

Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately. Wichmann recently served as chief executive officer of...

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021. Mike Mahoney, chairman and chief executive officer,...

Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On May 11, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28,...

Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of...

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of...

Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional,...

Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This...

Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Mike Mahoney, chairman and chief...

Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in...

MARLBOROUGH, Mass., December 2, 2020 – Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney, chairman and chief executive officer, and Susie...

Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and...

Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with...

Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT....

Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali,...

Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...

Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed...

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...

Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent...

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020, Mike Mahoney, chairman and chief executive officer, and Susie Lisa,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an...

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Experience...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device...

Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to...

Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation...

Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald, executive vice president and president, Rhythm...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and...

Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming virtual investor conferences. On May 13, 2020, Dan Brennan, executive vice president and chief financial officer, and...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...

Boston Scientific Corporation (NYSE: BSX) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken to achieve its goal of global carbon neutral...

Boston Scientific Corporation (NYSE: BSX) today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held exclusively in a virtual meeting format at the previously...

The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...

Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019, Susie Lisa, vice president, Investor Relations, and...

Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). The Company has...

Boston Scientific Corporation (the "Company") (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this month. On November 5, 2019, Jeff Mirviss,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on a reported basis, 14.2 percent on an...

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2019 on Wednesday, October...

Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019 in Boston. Mike Mahoney, chairman and...

Boston Scientific Corporation (NYSE:BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS)...

Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and...

On August 7, 2019, the U.S. Food and Drug Administration (FDA) published guidance to physicians about the benefit-risk profile of peripheral paclitaxel devices intended for the treatment of...

Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston. Susie Lisa, vice president, Investor...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2019 on Wednesday, July 24,...

Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is...

We appreciate the perspectives shared about the safety and benefits of peripheral paclitaxel devices during the FDA’s meeting of the Circulatory System Devices Panel. Boston Scientific shares...

On June 19-20, 2019, the U.S. Food and Drug Administration (FDA) held a meeting of the Circulatory System Devices Panel about peripheral devices with paclitaxel. Although data on the Boston...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect...

Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City. Mike Mahoney, chairman and chief...

Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System for...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City. Art Butcher, senior vice president and president,...

Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San...

Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an...

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a...

On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse (POP) to stop selling and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24,...